Ohr Pharmaceutical to Announce Fiscal Third Quarter 2017 Results on August 8
July 31, 2017 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that...
Ohr Pharmaceutical to Present at the 2017 Marcum Microcap Conference
June 12, 2017 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, June 12, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that...
Ohr Pharmaceutical Announces Appointment of Hon. Mike Ferguson as Chairman of the Board of Directors
May 11, 2017 16:15 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 11, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced the...
Ohr Pharmaceutical Announces Fiscal Second Quarter 2017 Earnings
May 11, 2017 16:01 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 11, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today reported results...
Ohr Pharmaceutical to Announce Fiscal Second Quarter 2017 Results on May 11
May 09, 2017 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that it...
Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD
April 10, 2017 16:15 ET
|
Ohr Pharmaceutical, Inc.
Results from Ongoing Clinical Trial in Wet-AMD (The MAKO Study) Expected by the End of Calendar 2017 or Early 2018Company Now Fully Funded Through Efficacy Data From Ongoing Trial and Into 2018 NEW...
Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants
April 10, 2017 16:01 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, April 10, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it has closed its previously announced...
Ohr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants
April 05, 2017 09:22 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, April 05, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it has priced a registered public...
Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants
April 04, 2017 16:01 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, April 04, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it intends to offer shares of its common...
Ohr Pharmaceutical to Present at the Cowen & Company 37th Annual Health Care Conference
March 02, 2017 09:38 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that...